Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Ticker
EW
Exchange
NYSE
Sector
Healthcare
Industry
Medical Devices
Market cap
$60.69B
52-week range
$74.66 - $108.00

Valuation

Share price
$105.23 (close of Nov 18, 2026)
P/E (TTM)
59.56x
Price to book
5.54x
Price to free cash flow
42.61x
Enterprise value
$56.75B
Book value per share
$19.04

Price performance

PeriodChange
1 day-0.19%
5 days-0.55%
1 month+21.51%
3 months+15.66%
6 months+27.72%
Year to date+23.44%
1 year+25.21%
3 years+57.29%
5 years-10.08%
10 years+254.55%
All time+7,553.09%

Short interest

As of
Oct 30, 2026
Short % of float
1.86%
Shares short
9.38M
Days to cover
2.80
Change since prior report
+0.52%
Source
FINRA consolidated short interest

Members of Congress who disclosed EW trades

Bruce Westerman · Jefferson Shreve · Alan Armstrong · Josh Gottheimer · Robert Bresnahan

Super investors holding EW

Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · David Rolfe (Wedgewood Partners Inc)

Profitability and growth

Return on equity
10.38%
Return on invested capital
9.48%
Return on assets
7.84%
Return on capital employed
10.64%
Gross margin
78.01%
Net margin
17.69%
EBITDA margin
23.42%
Revenue growth
11.55%
Net income growth
-74.28%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.35%
Current ratio
4.60x
Net debt to EBITDA
-2.25x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$6.07B
Cost of revenue
$1.33B
Gross profit
$4.73B
EBITDA
$1.42B
Net income
$1.07B
Earnings per share
$1.84
Research and development
$1.08B
Interest expense
$20.40M
Shares outstanding
584.80M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$6.07B$4.73B$1.07B$1.84
2024-12-31$5.44B$4.32B$4.17B$6.98
2023-12-31$5.01B$4.03B$1.40B$2.31
2022-12-31$4.46B$3.74B$1.52B$2.46
2021-12-31$5.23B$3.98B$1.50B$2.41
2020-12-31$4.39B$3.31B$823.40M$1.32
2019-12-31$4.35B$3.23B$1.05B$1.68
2018-12-31$3.72B$2.78B$722.20M$1.15
2017-12-31$3.44B$2.56B$583.60M$0.92
2016-12-31$2.96B$2.17B$569.50M$0.89

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3178.01%17.69%10.38%9.48%
2024-12-3179.46%76.75%41.49%11.40%
2023-12-3180.47%27.99%20.87%15.62%
2022-12-3183.79%34.09%26.21%20.05%
2021-12-3176.13%28.73%25.76%22.85%
2020-12-3175.36%18.77%18.00%15.26%
2019-12-3174.37%24.08%25.24%21.28%
2018-12-3174.77%19.40%23.00%18.99%
2017-12-3174.52%16.99%19.74%15.98%
2016-12-3173.09%19.22%21.74%16.94%

Cash and debt by year

Period endCashDebt
2025-12-31$4.23B$598.30M
2024-12-31$3.98B$597.70M
2023-12-31$1.63B$597.00M
2022-12-31$1.22B$596.30M
2021-12-31$1.47B$595.70M
2020-12-31$1.40B$595.00M
2019-12-31$1.52B$594.40M
2018-12-31$956.50M$593.80M
2017-12-31$1.34B$438.40M
2016-12-31$1.27B$822.30M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.33B$158.10M
2024-12-31$289.90M$162.30M
2023-12-31$642.80M$139.40M
2022-12-31$973.60M$126.80M
2021-12-31$1.41B$109.30M
2020-12-31$647.30M$92.60M
2019-12-31$928.50M$81.30M
2018-12-31$688.00M$71.00M
2017-12-31$832.60M$61.60M
2016-12-31$528.30M$56.90M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-04Sep 2026$0.73
2026-07-23Jun 2026$0.73
2026-04-23Mar 2026$0.75
2026-02-10Dec 2025$0.62
2025-10-30Sep 2025$0.59
2025-07-24Jun 2025$0.62
2025-04-23Mar 2025$0.60
2025-02-11Dec 2024$0.55

Filings and sources

Company website
edwards.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

GE HealthCare Technologies Inc. (GEHC) · Boston Scientific Corp (BSX) · Dexcom Inc (DXCM) · Stryker Corp (SYK) · STERIS plc (STE) · Medtronic plc (MDT) · Zimmer Biomet Holdings, Inc. (ZBH) · Abbott Laboratories (ABT)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades